Vibegron for ENergy Thinking and Resilience in Aging
ConditionObesity
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age45-75
SponsorWake Forest University Health Sciences
About this trial
This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.
Eligibility criteria
Qualifiers
Obese (BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with a waist circumference >102 cm for men and >88 cm for women)
Disqualifiers
Body weight ≥450 pounds
Major depression
Evidence of cognitive impairment
Uncontrolled diabetes (hemoglobin A1c >7%)
Trial design
Treatments tested in this trial
- Vibegron
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov